Literature DB >> 21109934

Overexpression of fibroblast growth factor receptor 4 in high-grade pancreatic intraepithelial neoplasia and pancreatic ductal adenocarcinoma.

Norio Motoda1, Yoko Matsuda, Munehiko Onda, Toshiyuki Ishiwata, Eiji Uchida, Zenya Naito.   

Abstract

The overexpression of fibroblast growth factor receptor (FGFR) 4 has been reported in various human cancers, but it has not been studied in pancreatic ductal adenocarcinoma (PDAC) or its precursor lesion, pancreatic intraepithelial neoplasia (PanIN). Moreover, there is controversy as to whether FGFR4 has a mitogenic role in carcinogenesis or other functions. Therefore, the expression and roles of FGFR4 in pancreatic cancer were investigated. Immunohistochemical staining was performed using an anti-FGFR4 antibody in PDAC and PanIN cases. The expression levels of FGFR4 mRNA and protein were investigated in PDAC cell lines by qRT-PCR and Western blot, respectively. Changes were analyzed in cell morphology, proliferation, migration, invasion and attachment in PDAC cell lines with or without the stimulation of FGFR4 by FGF19, as a known specific ligand. The changes in mRNA levels associated with transformation and tumorigenesis as a result of FGF19 administration were also evaluated. FGFR4 was expressed in 39 of 53 PDAC cases (73.6%) and its expression tended to be related to longer overall survival (P=0.068). Moreover, it was frequently expressed in high-grade PanIN lesions [10 of 11 lesions (90.9%)], whereas it was hardly expressed in low-grade PanIN lesions [1 of 10 lesions (10.0%)] (P=0.0003). FGFR4 stimulation of PDAC cells resulted in significantly increased cell adhesion to laminin and fibronectin (P<0.05) and decreased cell migration (P<0.05). The results of PCR array analysis indicated that this was a result of up-regulation of the integrin α4 family. In contrast, cell morphology or proliferation in PDAC cells was not affected. We showed that FGFR4 expression is markedly increased in high-grade PanIN and PDAC compared with that in normal and low-grade PanIN, and that FGFR4 stimulation by FGF19 of PDAC cells contributes to tumor suppression by increasing cell adhesion to extracellular matrix.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21109934

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  16 in total

Review 1.  FGFR4: A promising therapeutic target for breast cancer and other solid tumors.

Authors:  Kevin M Levine; Kai Ding; Lyuqin Chen; Steffi Oesterreich
Journal:  Pharmacol Ther       Date:  2020-05-31       Impact factor: 12.310

2.  Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors.

Authors:  Li Tan; Jun Wang; Junko Tanizaki; Zhifeng Huang; Amir R Aref; Maria Rusan; Su-Jie Zhu; Yiyun Zhang; Dalia Ercan; Rachel G Liao; Marzia Capelletti; Wenjun Zhou; Wooyoung Hur; NamDoo Kim; Taebo Sim; Suzanne Gaudet; David A Barbie; Jing-Ruey Joanna Yeh; Cai-Hong Yun; Peter S Hammerman; Moosa Mohammadi; Pasi A Jänne; Nathanael S Gray
Journal:  Proc Natl Acad Sci U S A       Date:  2014-10-27       Impact factor: 11.205

3.  Expression of fibroblast growth factor receptor 4 and clinical response to lenvatinib in patients with anaplastic thyroid carcinoma: a pilot study.

Authors:  Haruhiko Yamazaki; Tomoyuki Yokose; Hiroyuki Hayashi; Hiroyuki Iwasaki; Sachie Osanai; Nobuyasu Suganuma; Hirotaka Nakayama; Katsuhiko Masudo; Yasushi Rino; Munetaka Masuda
Journal:  Eur J Clin Pharmacol       Date:  2020-02-07       Impact factor: 2.953

4.  Oncogenic RAS pathway activation promotes resistance to anti-VEGF therapy through G-CSF-induced neutrophil recruitment.

Authors:  Vernon T Phan; Xiumin Wu; Jason H Cheng; Rebecca X Sheng; Alicia S Chung; Guanglei Zhuang; Christopher Tran; Qinghua Song; Marcin Kowanetz; Amy Sambrone; Martha Tan; Y Gloria Meng; Erica L Jackson; Franklin V Peale; Melissa R Junttila; Napoleone Ferrara
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-25       Impact factor: 11.205

Review 5.  Is fibroblast growth factor receptor 4 a suitable target of cancer therapy?

Authors:  Christine Heinzle; Zeynep Erdem; Jakob Paur; Bettina Grasl-Kraupp; Klaus Holzmann; Michael Grusch; Walter Berger; Brigitte Marian
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

6.  Fundamentals of FGF19 & FGF21 action in vitro and in vivo.

Authors:  Andrew C Adams; Tamer Coskun; Armando R Irizarry Rovira; Michael A Schneider; David W Raches; Radmila Micanovic; Holly A Bina; James D Dunbar; Alexei Kharitonenkov
Journal:  PLoS One       Date:  2012-05-31       Impact factor: 3.240

7.  Maelstrom promotes tumor metastasis through regulation of FGFR4 and epithelial-mesenchymal transition in epithelial ovarian cancer.

Authors:  Wei-Peng He; Gui-Ping Yang; Zun-Xian Yang; Hong-Wei Shen; Ze-Shan You; Guo-Fen Yang
Journal:  J Ovarian Res       Date:  2022-05-06       Impact factor: 4.234

8.  Established gastric cancer cell lines transplantable into C57BL/6 mice show fibroblast growth factor receptor 4 promotion of tumor growth.

Authors:  Masami Yamamoto; Sachiyo Nomura; Akihiro Hosoi; Koji Nagaoka; Tamaki Iino; Tomohiko Yasuda; Tomoko Saito; Hirokazu Matsushita; Eiji Uchida; Yasuyuki Seto; James R Goldenring; Kazuhiko Kakimi; Masae Tatematsu; Tetsuya Tsukamoto
Journal:  Cancer Sci       Date:  2018-04-15       Impact factor: 6.716

9.  FGFR4 and TGF-β1 expression in hepatocellular carcinoma: correlation with clinicopathological features and prognosis.

Authors:  Zhixin Chen; Bao Xie; Qinhua Zhu; Qinghai Xia; Songmin Jiang; Ruoyu Cao; Lihua Shi; Dansi Qi; Xiaokun Li; Lin Cai
Journal:  Int J Med Sci       Date:  2013-11-12       Impact factor: 3.738

10.  Crystal Structure of the FGFR4/LY2874455 Complex Reveals Insights into the Pan-FGFR Selectivity of LY2874455.

Authors:  Daichao Wu; Ming Guo; Michael A Philips; Lingzhi Qu; Longying Jiang; Jun Li; Xiaojuan Chen; Zhuchu Chen; Lin Chen; Yongheng Chen
Journal:  PLoS One       Date:  2016-09-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.